Latest Period
Q1 2026
Security Snapshot
GT Biopharma, Inc. - Common Stock (GTBP) Institutional Ownership
CUSIP: 36254L308
13F Institutional Holders and Ownership History from Q4 2023 to Q1 2026
Institutions Reporting
39
Shares (Excl. Options)
1,613,044
Price
$0.41
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- GTBP on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 1,613,044
- Total 13F value
- $656,720
- Portfolio coverage rank
- 0%
- Share change
- +454,220
- Value change
- +$139,088
- Number of holders
- 39
- Shares outstanding
- 3,148,458
- SEC-reported price per share
- $0.31
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- GTBP - GT Biopharma, Inc. - Common Stock is tracked under CUSIP 36254L308.
- 39 institutions reported positions in Q1 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 38 to 39 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $373,734 to $656,720.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 39 institutions filings for Q1 2026.
Security key
36254L308
Latest holder period
Q1 2026
13F holders
39
13D/G owners
3
CIK / CUSIP context first
Open Q1 2026 holders
GTBP full holder history
GT Biopharma, Inc. SEC filings
GT Biopharma, Inc. company facts
GT Biopharma, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 36254L308:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
GTBP
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Five Narrow Lane LP | 10% | $552,386 | 253,388 | Five Narrow Lane LP | 13 May 2025 | |||
| CYTOVANCE BIOLOGICS INC | 9.8% | $478,416 | 219,457 | CYTOVANCE BIOLOGICS INC | 30 Sep 2024 | |||
| BRISTOL INVESTMENT FUND LTD | 2.4% | $171,405 | 74,524 | Bristol Investment Fund, Ltd. | 29 May 2025 |
As of 31 Mar 2026, 39 institutional investors reported holding 1,613,044 shares of GT Biopharma, Inc. - Common Stock (GTBP). This represents 51% of the company’s total 3,148,458 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
50%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 14% | 451,875 | 0% | 0% | $184,365 |
| GEODE CAPITAL MANAGEMENT, LLC | 9.4% | 294,459 | +1429% | 0% | $120,170 |
| VANGUARD FIDUCIARY TRUST CO | 7.2% | 225,938 | 0% | 0% | $92,183 |
| Arax Advisory Partners | 3% | 93,627 | 0% | $38,210 | |
| CITADEL ADVISORS LLC | 2.1% | 66,165 | -18% | 0% | $27,002 |
| SeaCrest Wealth Management, LLC | 1.6% | 50,000 | 0% | 0% | $20,405 |
| UBS Group AG | 1.5% | 45,970 | +4596900% | 0% | $18,756 |
| TWO SIGMA SECURITIES, LLC | 1% | 31,796 | +154% | 0% | $12,976 |
| LPL Financial LLC | 0.96% | 30,382 | +186% | 0% | $12,399 |
| Invst, LLC | 0.74% | 23,400 | 0% | $9,550 | |
| OSAIC HOLDINGS, INC. | 0.67% | 21,000 | +950% | 0% | $8,572 |
| Keel Point, LLC | 0.66% | 20,768 | 0% | $8,475 | |
| Cerity Partners LLC | 0.64% | 20,023 | +33% | 0% | $8,171 |
| Integrated Wealth Concepts LLC | 0.64% | 20,006 | 0% | 0% | $8,164 |
| Private Wealth Management Group, LLC | 0.64% | 20,000 | 0% | $8,162 | |
| Coston, McIsaac & Partners | 0.54% | 17,092 | 0% | 0% | $6,000 |
| MORGAN STANLEY | 0.53% | 16,599 | -11% | 0% | $6,774 |
| Caitlin John, LLC | 0.52% | 16,500 | 0% | 0% | $6,734 |
| WELLS FARGO & COMPANY/MN | 0.51% | 16,037 | 0% | 0% | $6,545 |
| AM INVESTMENT STRATEGIES LLC | 0.48% | 15,000 | 0% | 0% | $6,000 |
| Virtu Financial LLC | 0.47% | 14,876 | 0% | $6,000 | |
| StoneX Group Inc. | 0.47% | 14,756 | 0% | $6,022 | |
| Verdence Capital Advisors LLC | 0.38% | 12,000 | -7.7% | 0% | $4,897 |
| Prospera Financial Services Inc | 0.38% | 11,996 | 0% | 0% | $4,893 |
| LaSalle St. Investment Advisors, LLC | 0.35% | 11,000 | 0% | $4,489 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
10
Latest
Q1 2026
Rows shown
1-10 of 10
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 1,613,044 | $656,720 | +$139,088 | $0.41 | 39 |
| 2025 Q4 | 483,011 | $373,734 | +$113,728 | $0.79 | 38 |
| 2025 Q3 | 369,208 | $217,520 | +$21,414 | $0.59 | 20 |
| 2025 Q2 | 198,676 | $711,263 | +$381,370 | $3.58 | 21 |
| 2025 Q1 | 99,688 | $220,497 | -$29,000,935 | $2.15 | 20 |
| 2024 Q4 | 1,244,880 | $29,297,553 | +$4,192 | $3.05 | 18 |
| 2024 Q3 | 1,246,007 | $35,300,829 | +$5,339,749 | $2.31 | 15 |
| 2024 Q2 | 1,080,160 | $38,124,773 | +$37,905,403 | $2.83 | 16 |
| 2024 Q1 | 75,442 | $348,558 | +$348,261 | $4.43 | 15 |
| 2023 Q4 | 208 | $53 | +$53 | $0.26 | 2 |